Zacks Investment Research Lowers Imago BioSciences (NASDAQ:IMGO) to Sell

Zacks Investment Research lowered shares of Imago BioSciences (NASDAQ:IMGO) from a hold rating to a sell rating in a research report sent to investors on Wednesday, Zacks.com reports.

According to Zacks, “Imago BioSciences Inc. is a clinical stage biopharmaceutical company. It involved in discovering new medicines for the treatment of myeloproliferative neoplasms. Imago BioSciences Inc. is based in SOUTH SAN FRANCISCO, Calif. “

Separately, Jefferies Financial Group reaffirmed a buy rating and issued a $37.00 price target on shares of Imago BioSciences in a report on Monday, December 13th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of Buy and an average price target of $34.33.

IMGO opened at $18.48 on Wednesday. Imago BioSciences has a 1-year low of $14.61 and a 1-year high of $35.68. The business has a 50 day moving average price of $21.82.

Imago BioSciences (NASDAQ:IMGO) last posted its quarterly earnings results on Wednesday, November 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.10). Equities analysts predict that Imago BioSciences will post -2.27 EPS for the current fiscal year.

In other Imago BioSciences news, insider Jennifer Peppe sold 14,000 shares of the company’s stock in a transaction on Wednesday, January 12th. The stock was sold at an average price of $19.95, for a total value of $279,300.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Large investors have recently made changes to their positions in the business. Citigroup Inc. acquired a new stake in Imago BioSciences during the 3rd quarter valued at $30,000. Morgan Stanley acquired a new stake in Imago BioSciences during the 3rd quarter valued at $50,000. California State Teachers Retirement System acquired a new stake in Imago BioSciences during the 3rd quarter valued at $106,000. American International Group Inc. acquired a new stake in Imago BioSciences during the 3rd quarter valued at $107,000. Finally, Deutsche Bank AG acquired a new stake in Imago BioSciences during the 3rd quarter valued at $112,000. 71.11% of the stock is currently owned by institutional investors.

Imago BioSciences Company Profile

Imago BioSciences Inc is a clinical stage biopharmaceutical company. It involved in discovering new medicines for the treatment of myeloproliferative neoplasms. Imago BioSciences Inc is based in SOUTH SAN FRANCISCO, Calif.

Featured Story: Options Trading

Get a free copy of the Zacks research report on Imago BioSciences (IMGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.